Key result
GLP-1 receptor agonists reduce major cardiovascular events and HF complications, but GI side effects limit adherence.
Why the study?
Translating the cardioprotective benefits of GLP-1RAs from clinical trials into routine practice reveals a marked gap between efficacy and effectiveness, primarily driven by suboptimal patient persistence and adherence.
This narrative review outlines a practical prescribing framework focusing on patient selection, gradual dose titration, and symptom management to bridge the gap between trial efficacy and real-world adherence for GLP-1 receptor agonists in cardiovascular practice.
Answers are grounded in this paper and cite their sources.
May improve CV outcomes in T2D with ASCVD if GI effects managed; leaves open optimal real-world adherence strategies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have fundamentally transformed modern cardiometabolic care, moving beyond glycemic control to become a cornerstone of obesity management and potent cardiovascular risk reduction. Large-scale clinical trials consistently highlight their cardioprotective benefits, demonstrating significant reductions in major adverse cardiovascular events (MACE), cardiovascular mortality, and obesity-related heart failure complications. However, translating these remarkable clinical trial successes into routine clinical practice reveals a marked gap between efficacy and effectiveness, primarily driven by suboptimal patient persistence and adherence. This narrative review synthesizes current evidence regarding the pharmacology, safety, tolerability, adherence, and patient selection of GLP-1RAs to support optimal therapeutic decision-making in cardiovascular practice. While long-term data disprove clear causal relationships with pancreatic or thyroid malignancies, a high incidence of predictable, dose-related gastrointestinal adverse events (nausea, vomiting, diarrhea) remains the leading cause of early treatment discontinuation. Additionally, treatment persistence in clinical practice is heavily influenced by financial burdens, supply chain instability, and formulation choices. Cardioprotective benefits are well-established for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Mitigating challenges in clinical practice requires a systematic, multi-step prescribing framework focused on targeted patient selection, gradual individualized dose titration (“start low and go slow”), and proactive multidisciplinary symptom management.
No takes yet. Share an insight, caveat, or question.
Pejčić et al. (2026) conducted a review in Cardiometabolic disease, obesity, type 2 diabetes, and atherosclerotic cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) was evaluated on Major adverse cardiovascular events (MACE), cardiovascular mortality, and obesity-related heart failure complications. GLP-1 receptor agonists reduce major cardiovascular events, CV mortality, and obesity-related HF complications, though routine adherence is limited by GI adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: